Lynch Regenerative Medicine Completes Phase II Wound Trial
FRANKLIN, Tenn., August 18, 2026 Lynch Regenerative Medicine (LRM) announced the completion of enrollment in an investigator-initiated Phase II...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
FRANKLIN, Tenn., August 18, 2026 Lynch Regenerative Medicine (LRM) announced the completion of enrollment in an investigator-initiated Phase II...
SEATTLE, Washington & CAMBRIDGE, UK, May 1, 2026 Pluristyx and Qkine announced a reciprocal distribution agreement aimed at streamlining...
